





CORPORATE PRESENTATION

March 2021

- > SLEEP DIAGNOSTICS & TREATMENT
- > NEURO DIAGNOSTICS
- > BRAIN RESEARCH
- > ULTRASONIC BLOOD FLOW MONITORING
- > MEDICAL INNOVATIONS



OVER
30
YEARS
OF EXCELLENCE
IN DIAGNOSTICS

Who is Compumedics?

A leading global, innovative developer and manufacturer of medical devices for:

Diagnosing
sleep disorders

Monitoring neurological
disorders including
long-term epilepsy
monitoring (LTEM)

Highly sophisticated
brain research

Ultrasonic monitoring
of blood flow through
the brain (Transcranial
Doppler [TCD])

A technological leader in its chosen markets:

#1 Australian sleep &
neuro diagnostics
device supplier

#1 Japan sleep
diagnostics device
supplier

#1 China sleep
diagnostic device
supplier to premier
facilities & #1 TCD
device supplier

#3 USA sleep
diagnostic device
supplier and emerging
#3 supplier for
neurological monitoring
devices

— 130 employees across four locations, Melbourne, Australia (Head Office), Charlotte, NC, USA, Hamburg, Dresden and Singen, Germany and Deajeon in South Korea

— Compumedics FY21 guidance is for revenues and underlying earnings to be greater than FY20

— Compumedics listed ASX Dec 21, 2000

H1 FY2021 – Performance Review

- H1 FY21 Revenue \$18.0m, EBITDA \$1.9m, NPAT \$1.3m

	H1 FY21	H1 FY20	Variance	Comment
Revenue – reported	\$18.3m	\$18.0m	-1%	The Company shipped revenues 1% lower than the prior half year, primarily due to logistical issues re the COVID-19 Pandemic in the northern hemisphere. Positively, sales orders taken for H1 FY21 were up 13% to \$20.3m.
EBITDA - reported	\$1.9m	\$1.2m	58%	EBITDA was higher due to increased margins at 56%, compared to 54% in H1 FY2 and on-going cost containment.
NPAT-reported	\$1.3m	\$0.2m	550%	NPAT was higher due to better underlying earnings and a swing in tax expense to tax benefit in the period.


H1 FY2021 – Performance Review

- Sales orders taken were 13% higher at \$20.3m for H1 FY21 compared to \$18.0m for H1 FY20. Sales orders taken were 183% higher in Europe, 23% higher in Australia and 2% higher in DWL
- Shipped and invoiced revenues decrease 1% – largely as a result of logistical issues associated with the COVID-19 Pandemic in the northern hemisphere. These sales orders have already or will ship in H2 FY21
- Profitability (EBITDA) improved to \$1.9m for H1 FY21 compared to \$1.2m for H1 FY20, as a result of increased gross margins to 56% from 54% and ongoing cost containment
- The Company received \$0.8m in JobKeeper payments in H1 FY21. The Company's eligibility for JobKeeper finished on 31 December 2020.
- Tax expense was a benefit of \$0.3m in H1 FY21, compared to a \$0.5 expense in H1 FY20

Sales Bridge Chart – H1 FY20 to H1 FY21



EBITDA movement – H1 FY20 to H1 FY21




H1 FY21 – Milestones achieved

- Core business: Profitability improves on stable sales with increasing sales orders taken, despite ongoing impacts of COVID-19 in the northern hemisphere in the 6 months to Dec 31, 2020
- MEG: Compumedics/Neuroscan dual helmet Dewar MEG system, with KRISS, now planning for second phase installation at Barrow Neurological Institute. The Company continues to pursue other near-term identified opportunities. FDA clearance achieved February 2020.
- eHealth: Nexus 360: sites continue to be added. Somfit® consumer sleep device: discussions continue to progress regarding commercialization activities


Revenue Composition at \$18.0m

31 December 2020

By geographic region



By product/market



Software upgrades 5 to 10% of system revenues. MEG included in Brain – Research

Compumedics sells directly to end-user customers in Australia, USA, France and Germany and through its network of more than 50 distributors to all other parts of the world

Core Business – Continuing Net Cash Position


\$m	FY16	H1 FY17	H1 FY18	H1 FY19	H1 FY20	H1 FY21
Cash	3.1	5.7	2.9	4.3	3.3	5.6
Trade receivables	11.9	10.9	14.8	15.5	17.3	13.3
Inventories	6.5	7.1	7.7	8.5	7.5	8.9
Prod. dev't	2.4	2.4	3.4	5.0	9.7	3.6
Tax asset	0.5	0.5	0.7	0.0	1.5	0.9
PP&E	0.8	0.8	0.6	0.9	0.9	1.1
Other	0.9	0.0	0.0	0.0	2.1	2.9
Assets	26.1	27.4	30.2	34.2	41.4	36.3
Trade cred.	4.1	3.0	4.4	3.7	3.7	3.9
Borrowings	2.6	1.0	0.8	1.8	1.8	3.7
Def. payment	2.0	1.3	1.3	1.3	1.6	1.8
Other	2.8	3.1	2.8	3.3	6.8	4.4
Total Liabilities	11.5	8.4	9.3	10.0	13.9	13.8
Net Assets	14.6	19.0	20.9	24.2	27.5	22.5
<i>Net Cash/Equity</i>	<i>-3%</i>	<i>-25%</i>	<i>-10%</i>	<i>-10%</i>	<i>-5%</i>	<i>-8%</i>

Outlook

- Profitability and operating cash to improve as impact of COVID-19 Pandemic abate
- New products in core were delayed but now expecting to be released by end of Calendar 2021
- MEG: Compumedics/Neuroscan second phase installation of Orion MEG system for Barrow Neurological Institute now being planned. The Company continues to pursue other near-term identified opportunities. FDA clearance achieved February 2020
- eHealth: Nexus 360: sites continue to be added. Somfit® consumer sleep device: discussions continue to progress regarding commercialization activities
- Specific full-year guidance not given, but Company expects revenues and underlying earnings to be greater than FY20.

Growth Platform – Core and Step-Out









Sales – schematic only



- **Step-out - NEURO – BRAIN IMAGING** – First phase installation at Barrow Neurological Institute in Phoenix, AZ, USA has been undertaken and the second and final phase is now being planned. 2nd and third sales opportunities being actively pursued.
- **Step-out - SLEEP - CLOUD GROWTH** – Nexus 360 cloud-based professional sleep diagnostic solution sold to more than 46 sites in US and Australia and generated revenues of \$1m in FY20. Annual contracted fees now over \$1.5m. Somfit development and discussions continue.
- **Core - SLEEP & NEURO – DIAGNOSTIC GROWTH** – Mid-market devices selling and expansion is resuming in China as COVID-19 abates and US expansion will resume as COVID-19 abates. Neurology remains a key focus for core business growth in Asia, China, US and other key markets.

*MEG = Magnetoencephalography

Core Business – Premium Focus

	Sleep Diagnostics	Neuro Diagnostics – Clinic	Neuro Diagnostics - Research	Brain Blood Flow Diagnostics
Global market – USD pa	250m	1,300m	20m	15m
Compumedics market share (approximate)				
Compumedics market position	Aust – 1 USA – 3 China - 1	Aust – 1 USA – 3 China - 1	Aust – 1 USA – 1 China – 1	Aust – 1 USA – 2 China – 1 Germany – 1
Business and product type	Capital equip – hardware and software	Capital equip – hardware and software	Capital equip – hardware and software	Capital equip – hardware and software
Annuity revenues – ~ % of total – supplies & support				

Core Business – Adding Mid-Tier Range

Product		Used for	Bought by	Average selling price
Grael		Sleep and neurology	Hospitals, doctors and service providers	USD17,500
Somte PSG		Sleep	Hospitals, doctors and service providers	USD10,000
Siesta		Sleep and neurology	Hospitals, doctors and service providers	USD18,000
Neuvo LTM		Neurology	Hospitals, doctors and service providers	USD35,000
Synamps RT		Brain Research	Universities and teaching hospitals	USD38,000
CURRY		Brain research and neurology	Universities, teaching and regular hospitals	USD20,000

Next Generation Growth – Core *and Step-out*

	Sleep Diagnostics	Neuro Diagnostics – Clinic	Neuro Diagnostics - Imaging	Brain Blood Flow Diagnostics
Next generation growth platform	Cloud based sleep diagnostic platforms for both professional and consumer applications	Long term epilepsy market penetration into US, Europe and Asia	Leverage CURRY software into full MEG solution with KRISS	Leverage existing TCD technology and patent to Traumatic Brain Injury (TBI) application
Market potential	Professional application > USD3bn pa <i>Consumer application > USD50bn pa</i>	Greater than USD100m pa	Research only USD100m pa <i>Brain Imaging >USD4bn pa</i>	Estimated cost of TBI's in the US alone greater than USD76bn pa
Business type	Services – fee per service	Capital equipment – bigger market	Capital equipment & Partnership – new market	Mixture of equipment and service fees

Core Business - Growth Drivers



Compumedics/Neuroscan innovative brain analysis software (CURRY 9 close to release) and high-performance amplifiers are unrivalled world class technology.



We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics.



Earnings initiatives to continue to flow through in FY21 – FY22. New ambulatory range releasing late 2021 and further manufacturing and operational efficiency gains to be implemented.



USA business growing with further modifications and enhancements to the team being implemented to support stronger growth across the entire business there as the pandemic is brought under control.



Continued expansion into untapped German market and ongoing growth in France.



Continuing growth in China for sleep diagnostics, with a stronger emphasis on the neuro diagnostic and monitoring market there.




Ideally positioned to accelerate organic growth and value realisation

USA – CMP is number 3 Supplier

USA Clinical Sales Force Expansion - Indicative

More sales representatives = more revenue for both sleep and neurology




China - We are the number 1 Premier Supplier

Compumedics Clients in China

- Sleep
- Neuroscience
- Neuroscan

China Sales (invoiced) – USD's



Step out 1 - Brain Imaging:

Opportunity

CMP's CURRY brain analysis software is already the gold standard for the MEG* market MRI** is too slow to capture dynamic brain activity needed for alzheimer's et al

CMP's agreement with KRISS provides access to a new and superior hardware platform

Compumedics can access a complete MEG sale (circa USD3 to 4m each) as opposed to the USD30k software sale

Market & Competition

The MEG market is currently estimated at about 20 systems a year at an average selling price of USD4.0m each = US\$80m/annum

This is expected to grow about 10% a year, excluding China

It is estimated that China could more than double the existing market size to about 50 units a year

The dominant existing player is Megian (previously Elekta). CTF MEG (is a much smaller player)

Plan

H2 FY19 – first phase of MEG installation undertaken at US based Barrow Neurological Institute (BNI)

Calendar 2021 – second and final phase of MEG installation planned to be undertaken at BNI

FY21/early FY22 – Secure second MEG sales

Outcome

CMP has sold and partially installed 1 MEG system in FY19

CMP has achieved FDA for Orion MEG

CMP expects to sell a further 1 MEG systems in early FY22

CMP expects to double sales in FY22/23 to 2 to 4 MEG systems



*MEG = Magnetoencephalography

**MRI = Magnetic resonance imaging

Step out 2 - eHealth – Cloud Sleep Diagnostics

Nexus 360 (professional cloud sleep diagnostics) sold into more than 46 US and Aust. sites with over 270 beds and generated revenues of \$1m in FY21

Contracted revenues now running at \$1.5m pa run rate as we exited FY20.

Operational systems have been developed for the cloud-based capture, transfer and translation of medical grade sleep parameters from any web-enabled device. The system can then store, analyse and interpret that data in a simple and actionable manner, reducing the need for on-site professionals.

Compumedics is continuing to seek appropriate third parties to expedite the process and take the Somfit consumer device to targeted market opportunities.

Key partners being pursued include web, telco, eHealth, consumer health/ electronics providers and device manufacturers.



Directors & Executive Team Key Management



Mr Tucson Dunn
Non Executive Director
CMP Tenure 12 months



David Burton, Ph.D.
Executive Chairman, CEO
Founder, Tenure 32 yrs



Mr. David Lawson
Chief Financial Officer
& Company Secretary
CMP Tenure 20 yrs



Mr. Warwick Freeman
Chief Technology Officer
CMP Tenure 26 yrs



Kerry Hubick, Ph.D.
Trademark, Patent &
General Legal Attorney
CMP Tenure 11 yrs



Mr. Christoph Witte
General Managing Director
Compumedics Germany GmbH
CMP/DWL - Tenure 29 yrs




Investor Summary

Core business continues to grow with lower cost base and addition of mid-tier

Compumedics remains committed to continuing to deliver superior returns to shareholders

Spin off/strategic decisions to unlock significant value, provide funds for growth and potentially capital returns to shareholders



International sales force expansion, neurology market opportunity and earnings improvement initiatives to continue to drive growth of core business

Brain imaging and e-Health are the next steps Moving 25+ years and \$100m+ in cumulative R&D to a modern platform to solve a massive and growing problems of neuro imaging in clinic and sleep disorders in the home

FY21 guidance: Revenues and underlying earnings to be greater than FY20



THANK YOU

Defining *Life's* Signals



OVER
30
YEARS
OF EXCELLENCE
IN DIAGNOSTICS

Disclaimer

This presentation has been prepared by Compumedics Ltd (CMP).

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statement. These forward-looking statement have been made based upon CMP's expectations and beliefs concerning future developments and their potential effect on CMP (and it's controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP's control. No assurance is given that future developments will be in accordance with CMP's expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.

Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.

